TUMOR NECROSIS FACTOR (TNF) BLOCKER
Avsola is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults and children with rheumatoid arthritis in combination with methotrexate. Avsola is also indicated to treat Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Avsola is also referred to by its drug name, infliximab-axxq.
Avsola is a member of a class of drugs called tumor necrosis factor (TNF) blockers. Avsola is believed to work by binding to and inhibiting TNF-alpha, reducing the normal functions of TNF including inflammation and immune response. Avsola is biologically similar to the FDA-approved drug Remicade (infliximab).
How do I take it?
Prescribing information states that Avsola is administered by intravenous infusion given once every several weeks.
Avsola comes as the form of an injection.
The FDA-approved label for Avsola lists common side effects including infections (such as sinus infections or upper respiratory infections), infusion-related reactions, headache, and abdominal pain.
Rare but serious side effects listed for Avsola include serious bacterial, viral, and fungal infections, other cancers, liver disease, heart failure and other cardiovascular problems, low white blood cell counts, lupus-like syndrome (which may resolve after stopping treatment), demyelinating disease (a disease of the nervous system), and allergic reaction to the infusion.
For more details about this treatment, visit:
Avsola — Amgen
Avsola — RxList